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ABSTRACT
Antibiotic resistant Klebsiella pneumoniae is a leading public health threat and gastrointestinal 
carriage is an established risk factor for subsequent infections during hospitalization. Our study 
contributes new knowledge of risk factors for gastrointestinal carriage and the genomic population 
structure of K. pneumoniae colonizing humans in a representative sample of a general population in 
a community setting. Altogether, 2,975 participants (54% women) >40 y in the population-based 
Tromsø Study: Tromsø7, Norway (2015–2016) were included. Fecal samples were screened for 
K. pneumoniae, which were characterized using whole-genome sequencing. Risk factors for carriage 
were analyzed using multivariable logistic regression on data from questionnaires and the 
Norwegian Prescription Database. Prevalence of K. pneumoniae gastrointestinal carriage was 
16.3% (95% CI 15.0–17.7, no gender difference). Risk factors associated with carriage included 
age ≥60 y, travel to Greece or Asia past 12 months (adjusted odds ratio 1.49, 95% CI 1.11–2.00), 
Crohn’s disease/ulcerative colitis (2.26, 1.20–4.27), use of proton pump inhibitors (1.62, 1.18–2.22) 
and non-steroidal anti-inflammatory drugs past 6 months (1.38, 1.04–1.84), and antibiotic use the 
last month (1.73, 1.05–2.86). Prevalence was higher among those having used combinations of drug 
classes and decreased over time with respect to preceding antibiotic use. The K. pneumoniae 
population was diverse with 300 sequence types among 484 isolates distributed across four 
phylogroups. Only 5.2% of isolates harbored acquired resistance and 11.6% had virulence factors. 
Identification of risk factors for gastrointestinal carriage allows for identification of individuals that 
may have higher risk of extraintestinal infection during hospitalization. The findings that specific 
diseases and drugs used were associated with carriage show an impact of these possibly through 
modulating the human gut microbiota promoting colonization. The diverse population structure of 
carriage isolates reflects the ecologically adaptive capacity of the bacterium and challenges for 
vaccine prospects and the identification of reservoirs as a potential source for human colonization.
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Klebsiella pneumoniae (Kp) is a key pathogen asso-
ciated with nosocomial infections frequently accom-
panied by antibiotic resistance.1,2 As an opportunistic 
pathogen, Kp is particularly problematic among neo-
nates, elderly, immunocompromised, and patients 
with underlying chronic diseases, and commonly 
causes pneumonia, urinary tract infections, and 
bacteremia.1 Additionally, the problem is exacerbated 
by the emergence and spread of community-acquired 
hypervirulent Kp causing infections in healthy indivi-
duals, usually presenting as pyogenic liver abscess 
occasionally accompanied with metastatic spread, 
but also as meningitis or endophthalmitis.3
Kp is known for its high prevalence and diversity 
of antibiotic resistance genes that challenge 
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treatment options due to infections with multi- 
drug resistant variants. In Europe, antibiotic resis-
tant Kp was responsible for more than 89,000 infec-
tions and 5,600 attributable deaths in 2015.4 Several 
new antibiotic resistance genes were first discov-
ered within Kp before spreading to other 
pathogens.5 Consequently, The World Health 
Organization considers antibiotic-resistant Kp as 
a critical-priority bacterium in antibiotic research 
and development.6
Recent taxonomic updates show that Kp subdi-
vides into five different species comprising seven 
phylogroups (Kp1-Kp7) referred to as the 
K. pneumoniae species complex (KpSC).7,8 The 
phylogroups include K. pneumoniae sensu stricto 
(Kp1), K. quasipneumoniae subsp. quasipneumo-
niae (Kp2), K. variicola subsp. variicola (Kp3), 
K. quasipneumoniae subsp. similipneumoniae 
(Kp4), K. variicola subsp. tropica (Kp5), 
‘K. quasivariicola’ (Kp6) and K. africana (Kp7).7– 
12 Herein, we refer to “Kp” for all members of the 
KpSC unless otherwise specified. Kp has a broad 
environmental distribution, and transmission 
routes to humans are currently not well defined.8
Gastrointestinal carriage of Kp as a reservoir for 
healthcare-associated Kp infections was established 
in the early 1970s.13 Recent genomic studies show 
that gastrointestinal carriage is a risk factor for 
subsequent extraintestinal infections, and ~50% of 
Kp bloodstream infections are caused by the 
patient’s own gut isolates.14,15 Moreover, the rela-
tive abundance of Kp in the gastrointestinal tract is 
associated with an increased risk of Kp 
bacteremia.16
Cross-sectional studies have shown that Kp gas-
trointestinal carriage prevalence varies from 6% to 
88% depending on geographical locations, detec-
tion methods and the populations 
investigated.14,15,17–19 However, we have a sparse 
understanding of risk factors for Kp gastrointest-
inal carriage and the population structure of Kp in 
the general human population. In a recent cross- 
sectional study of 911 pregnant women in low- 
income countries, Huynh et al. identified various 
country-specific environmental exposure factors 
linked to Kp gastrointestinal carriage and 
a diverse Kp population structure.19
Here, we investigated the prevalence of Kp car-
riage and associated risk factors among 2,975 
participants in a cross-sectional study of 
a representative sample of a general adult popula-
tion in Norway, a country with a low prevalence of 
antibiotic resistance and restricted antibiotic use. 
Additionally, we elucidated the Kp genomic popu-
lation structure of carriage isolates.
Results
We analyzed data from 2,975 participants (1,615 
women, 54.3%, Suppl. Table 1) 40 y and older. 
Median age of the participants was 65.0 y 
(Interquartile Range 59–71 y, no gender differ-
ence). Altogether, we identified 484 Kp carriers 
corresponding to a prevalence of 16.2% (95% CI 
14.5–18.1) among women and 16.3% (14.4–18.4) 
among men.
Kp gastrointestinal carriage and associated factors
In analysis adjusting for all of the explanatory vari-
ables (Suppl. Figure 1), Kp gastrointestinal carriage 
was associated with age 60 y and older (compared 
to the reference group 40–49 y), self-reported travel 
to Greece or Asia during the preceding 12 months 
(AOR 1.49, 1.11–2.00) and Crohn’s disease/ulcera-
tive colitis (2.26, 1.20–4.27) (Table 1). Furthermore, 
carriage was associated with the use of proton 
pump inhibitors (PPIs) (1.62, 1.18–2.22) and non- 
steroidal anti-inflammatory drugs (NSAIDs) (1.38, 
1.04–1.84) in the past 6 months, and antibiotic use 
in the last month (1.73, 1.05–2.86).
Analysis of the significant variables in the multi-
variable model for the three most frequent species 
(Kp1, Kp2 and Kp3) is presented in Suppl. Table 2. 
In this descriptive analysis, we compared partici-
pants colonized by a single phylogroup to Kp non- 
carriers, excluding carriers of any other phy-
logroup. Kp1 was the dominating phylogroup 
responsible for the associations to selected vari-
ables, except for NSAID use which is solely signifi-
cantly associated with Kp2. Kp3 is associated with 
PPI and antibiotic use.
The Kp prevalence of the three statistically sig-
nificantly associated drug classes (usage in past 6 
months) in relation to Kp carriage is shown in 
Figure 1. Kp prevalence was 16.1% among 286 
antibiotic-only users, 17.4% among 305 NSAID- 
only users, and 21.5% among 209 PPI-only users. 
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Kp prevalence increased in each overlapping area 
for two drug classes, and further increased to 30.8% 
in the overlapping area for all three.
Looking at the cumulative change in proportion 
of Kp carriers associated with antibiotic use during 
1–12 months before fecal sampling, we found that 
Kp carriage prevalence was highest among those 
with antibiotic use in the past month (28.4%) and 
past 2 months (25.0%), decreasing to around 20.0% 
in the past 6–12 months (Figure 2). In contrast, 
prevalence of Kp carriage was significantly lower 
(15.2%) in the non-antibiotic using population.
Table 1. K. pneumoniae (Kp) gastrointestinal carriage and associated factors among 2,975 participants in the Tromsø Study: Tromsø7 in 
crude and multivariable logistic regression analyses.
% (Kp) n (Kp) N OR 95% CI p-Value AOR 95% CI p-Value
Age (y) 0.024 0.128
40–49 10.8 37 344 1.00 1.00
50–59 15.4 67 435 1.51 0.98–2.32 1.34 0.85–2.11
60–69 17.3 222 1,286 1.73 1.20–2.51 1.56 1.06–2.30
70–84 17.4 158 910 1.74 1.19–2.55 1.56 1.03–2.36
Current daily smoking 0.798 0.717
No 16.2 421 2,598 1.00 1.00
Yes 15.7 55 351 0.96 0.71–1.31 0.94 0.66–1.34
Alcohol consumption frequency 0.021 0.050
Never to < monthly 16.4 164 998 1.00 1.00
2–4/month to 2–3/week 16.9 298 1,765 1.03 0.84–1.27 1.13 0.88–1.46
≥4/week 9.1 18 198 0.51 0.31–0.85 0.61 0.35–1.05
Alcohol units/occasion 0.501 0.365
1–4 16.2 412 2,540 1.00 1.00
≥5 14.1 20 142 0.85 0.52–1.37 0.79 0.47–1.32
Travel abroad past 12 monthsa 0.024 0.009
No 15.5 196 1,276 1.00 1.00
Greece or Asia 20.3 102 502 1.39 1.07–1.82 1.49 1.11–2.00
All other countries 15.3 179 1,171 0.99 0.79–1.23 0.97 0.76–1.26
Hospitalization past 12 months 0.145 0.844
No 15.9 412 2,588 1.00 1.00
Yes 19.0 67 353 1.24 0.93–1.65 1.03 0.74–1.44
Diabetes mellitusb 0.011 0.056
No 16.0 427 2,674 1.00 1.00
Yes 23.5 40 170 1.62 1.12–2.34 1.82 0.99–3.36
Crohn’s disease/ulcerative colitis 0.012 0.012
No 16.0 452 2,831 1.00 1.00
Yes 28.3 17 60 2.08 1.18–3.68 2.26 1.20–4.27
Proton pump inhibitors past 6 monthsc <0.001 0.003
No 15.3 404 2,632 1.00 1.00
Yes 23.3 80 343 1.68 1.28–2.20 1.62 1.18–2.22
NSAIDs past 6 monthsd 0.016 0.028
No 15.6 397 2,545 1.00 1.00
Yes 20.2 87 430 1.37 1.06–1.78 1.38 1.04–1.84
Antibiotic systemic use past 1 monthe 0.001 0.032
No 15.8 453 2,866 1.00 1.00
Yes 28.4 31 109 2.12 1.38–3.25 1.73 1.05–2.86
Metformin past 6 monthsf 0.090 0.764
No 16.0 460 2,867 1.00 1.00
Yes 22.2 24 108 1.50 0.94–2.38 0.89 0.40–1.95
Thyroid hormones past 6 monthsg 0.065 0.333
No 15.9 431 2,714 1.00 1.00
Yes 20.3 53 261 1.35 0.98–1.86 1.20 0.83–1.75
N, denominator; OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; NSAIDs, non-steroidal anti-inflammatory drugs. 
AOR adjusted for age, current daily smoking, alcohol consumption frequency, alcohol units/occasion, travel abroad past 12 months, hospitalization 
past 12 months, diabetes mellitus, Crohn’s disease/ulcerative colitis and drug use according to the Norwegian Prescription Database (A02BC, M01, 
J01, A07AA09, P01AB01, A10BA02, H03AA). 
The multivariable model contains 2,446 participants with complete information on all variables. 
aTraveled outside the Nordic countries >1 week duration in the past 12 months. 
b20 participants who answered “Yes, previously” were excluded. 
cA02BC, drugs used for peptic ulcer and gastro-esophageal reflux disease. 
dM01, anti-inflammatory and anti-rheumatic products (non-steroids), anti-inflammatory/anti-rheumatic agents in combination and specific anti- 
rheumatic agents. 
eJ01, A07AA09, P01AB01, antibacterials for systemic use, intestinal antiinfectives and nitroimidazole derivates used as antiprotozoals 
(metronidazole). 
fA10BA02, blood glucose lowering drug used in diabetes. 
gH03AA, natural and synthetic thyroid hormones.
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Figure 1. Proportional Venn diagram of Kp carriage prevalence related to statistically significantly associated drug classes (antibiotics 
(AB), nonsteroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs)) in the past 6 months among 2,975 study 
participants.
Figure 2. Cumulative change in the proportion of Kp carriers among those who had used antibiotics 1–12 months before the fecal 
sampling. Shaded gray area represents the 95% CI. The time period at each specified month includes data for the preceding months. 
The dashed black line indicates the prevalence of carriage in the non-antibiotic using population (15.2%).
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Kp phylogeny and diversity
Phylogenetic analysis based on whole-genome 
sequencing of 484 K. pneumoniae isolates identified 
three species distributed in four phylogroups with 
a predominance of K. pneumoniae sensu stricto 
(Kp1, 62.6%), followed by K. variicola subsp. var-
iicola (Kp3, 27.7%), K. quasipneumoniae subsp. 
quasipneumoniae (Kp2, 6.4%), and 
K. quasipneumoniae subsp. similipneumoniae 
(Kp4, 3.3%) (Figure 3, Suppl. Table 3). 
Phylogroups Kp5-Kp7 were not identified. Using 
multilocus sequence typing (MLST), we found 
a high degree of genotypic diversity (Simpson 
diversity index 99.5%) with a total of 300 different 
STs, including 96 (32%) novel STs (Suppl. 
Figure 2).20 The majority (79%) of the STs were 
represented by a single isolate. Only 17 STs (5.7%) 
were represented by more than five isolates. The 
most frequent were ST20 (n = 15, 3.1%), ST26 
(n = 13, 2.7%), ST35 (n = 9, 1.9%), ST37 (n = 9, 
1.9%), and ST2386 (n = 9, 1.9%). With regard to 
clonal relatedness, we found seven ST35 and three 
ST25 isolates with a range of zero to five SNPs 
(Suppl. Table 4), and seven to eight SNPs (Suppl. 
Table 5), respectively, indicating a recent clonal 
spread. No close clonal relatedness was identified 
among the remaining frequent STs (Suppl. 
Table 6).
Antimicrobial resistance and plasmid content
The prevalence of resistance was low and none of 
the isolates were resistant to cefotaxime, merope-
nem, aztreonam, or ciprofloxacin (Suppl. Figure 3). 
Resistance was observed against amoxicillin- 
clavulanic acid (0.6%), ceftazidime (0.2%), genta-
micin (0.4%), cefuroxime (0.6%), trimethoprim- 
sulfamethoxazole (1.7%), piperacillin-tazobactam 
(4.8%), and mecillinam (5.0%). This was in concor-
dance with the low number of intrinsic and 
acquired resistance genes (Figure 3, Suppl. 
Table 3). A high sequence diversity of species- 
specific intrinsic narrow-spectrum chromosomal β- 
lactamase gene alleles were identified (Suppl. 
Figures 4, 5, 6, and 7, Suppl. Table 3). Three ampi-
cillin-susceptible isolates harbored either deleted 
blaSHV/blaLEN genes or a premature stop codon in 
blaSHV. Only 5.2% of the isolates harbored an 
acquired resistance gene (median number: 2, 
Suppl. Table 3). BlaSHV-51 and blaSHV-52 were 
assigned by Kleborate as extended-spectrum β- 
lactamase and inhibitor-resistant β-lactamase, 
Figure 3. Core chromosomal maximum likelihood phylogeny of the 484 Kp genomes. The tips are colored by species. The heatmap 
shows presence (color) or absence (white) of acquired resistance genes (innermost ring) or virulence factors (remaining six rings). 
Clades corresponding to STs with five or more genomes are highlighted and labeled.
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respectively. However, both isolates were phenoty-
pically susceptible to all tested β-lactams and β- 
lactam-inhibitor combinations. Thirty-two plasmid 
replicon types were identified among 393/484 
(81.2%) isolates with IncFIB(K) (25.2%), Col 
(pHAD28) (15.0%), IncFIB(K) (pCAV1099-114) 
(11.4%), IncFIA (HI1) (10.5%), and IncFII 
(pKP91) (9.8%) the most frequent (Suppl. 
Table 3). The median number of replicon types 
per isolate was two.
Virulence factors and serotype prediction
The majority of isolates (n = 428, 88.4%) did not 
contain known acquired virulence determinants 
(Suppl. Table 3). Five K. pneumoniae sensu stricto 
isolates (1.0%) of different STs were defined as 
hypervirulent, including one isolate of the known 
hypervirulent ST23 clone.3 These five isolates har-
bored aerobactin (iuc1 or iuc2), salmochelin (iro1 
or iro2) and rmpA (Suppl. Table 3); three addition-
ally carried the yersiniabactin (ybt) locus. Three of 
the hypervirulent isolates harbored the capsular 
synthesis locus (KL) 1 or KL2, previously described 
as hypervirulence associated;3 the other two har-
bored KL23. Overall, the siderophore loci ybt, iuc, 
and iro were present in 10.7% (n = 52), 1.4% (n = 7), 
and 1.0% (n = 5) of the isolates, respectively (Suppl. 
Table 3). A total of 96 defined KL types were found 
(Suppl. Figure 8), with KL10 being the most fre-
quent (n = 21; 4.7%) followed by KL28 (n = 18; 
4.0%) and KL22 (n = 17; 3.8%). KL2 accounted for 
2.9% (n = 13) and KL1 for only 0.9% (n = 4). We 
observed 11 different defined O-antigen types in 
477 isolates (Suppl. Figure 9) with O1 (n = 133; 
27.9%) being the most frequent followed by O3/3a 
(n = 113; 23.7%), O2 (n = 76; 15.9%), O5 (n = 58; 
12.2%), and O3b (n = 47; 9.9%), accounting for 90% 
of the isolates. Five isolates harbored an O-locus 
with an unknown O-type.
Discussion
In this study of a large representative sample of 
a general population aged 40 y and older, we 
detected an overall Kp gastrointestinal carriage pre-
valence of 16.3% with no gender difference. We 
found that Kp carriage was associated with age 
60 y and older, reported Crohn’s disease/ulcerative 
colitis, travel to Asia and Greece in the preceding 
12 months, and recent use of PPIs, NSAIDs, and 
antibiotics. We showed that the Kp population 
among adults in the community setting in a high- 
income country with low antibiotic use was highly 
diverse and characterized by a low prevalence of 
acquired antibiotic resistance and virulence 
determinants.
The identified Kp carriage prevalence of 16.3% is 
lower than that observed among pregnant women 
in low-income countries (40–66%)19 and among 
healthy adults in Asian countries (19–88%),18 but 
in range with a hospital admission study in 
Australia (6–19%)14 and hospitalized patients in 
the USA (23%).15 This could be explained by the 
different populations investigated (e.g. healthy 
individuals, hospitalized patient groups, geographic 
setting, and/or ethnicity), but also by the sampling 
and detection strategies. Consistent with the cul-
ture-based Australian study of hospitalized patients 
on admission, we found that Kp carrier prevalence 
increased with age.14 The association of Kp gastro-
intestinal carriage with travel abroad, irrespective 
of resistance phenotype, has to our knowledge not 
been demonstrated before. The higher Kp preva-
lence associated with travel to Asia could be 
explained by the observed high carriage among 
people in this region.17–19
The increased prevalence of Kp carriage asso-
ciated with Crohn’s disease/ulcerative colitis could 
be due to disease-specific gut microbiota altera-
tions. The gut microbiota of patients with Crohn’s 
disease departs from the normal state as microbial 
diversity is significantly diminished including an 
increased abundance of Enterobacterales.21 
A review by Kaur et al. emphasizes the possible 
role of Kp in the pathogenesis of lower intestinal 
tract diseases.22 This corresponds to our findings of 
a higher Kp carrier prevalence among participants 
with self-reported Crohn’s disease/ulcerative coli-
tis. However, the pathogenesis of Crohn’s disease/ 
ulcerative colitis is complex and involves an inter-
play between different factors which may include 
the microbiota composition.23
A large number of non-antibiotic drugs have 
been shown to inhibit growth of one or more 
representative bacterial species in the human gas-
trointestinal tract.24 The positive association of PPI 
and/or NSAID use with Kp carriage further 
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underpins the influence of non-antibiotic drugs on 
fecal microbiota and the selection of specific bac-
terial species. PPI use is implicated in altered gut 
microbiota composition, bacterial colonization pat-
terns, including multi-drug resistant microorgan-
isms, and increased susceptibility to enteric 
bacterial infections.25–28 Although no direct evi-
dence exists, it may be possible that Kp as a major 
etiological agent of liver abscess,29 particularly in 
Asian countries, could be linked to the observation 
that PPI therapy is associated with an increased risk 
of cryptogenic liver abscess.30 The role of NSAIDs 
as a risk factor is unclear, but NSAID use has been 
shown to influence the gastrointestinal microbiota 
toward a higher relative abundance of 
Enterobacteriaceae.31 Interestingly, in the phy-
logroup subanalysis, we found NSAID users solely 
significantly associated with Kp2, compared to the 
other significant variables which were dominantly 
associated with Kp1 (Suppl. Table 2). However, the 
data must be interpreted with caution due to the 
low number of cases in some subgroups.
Systemic antibiotics more obviously influence 
the microbiota composition. Kp is intrinsically 
resistant to aminopenicillins and carboxypenicil-
lins, and thus has a selective advantage compared 
to other bacteria during treatment with penicillins, 
which constitutes approximately half of human 
antibiotic use in Norway.32 Antibiotics leave an 
imprint on the gastrointestinal bacterial commu-
nity after treatment is removed, ranging from 
weeks to years in different studies.33 This is consis-
tent with our finding of a significant increase in Kp 
prevalence related to antibiotic exposure even 
12 months prior to fecal sampling. Notably, our 
data display a quantitative time–response relation-
ship between antibiotic use and Kp carriage. The 
prevalence of Kp carriage decreased among indivi-
duals sampled from one to six-month post- 
exposure and reached a plateau at 5% above that 
of the non-antibiotic using population sampled at 
6–12 months post-exposure. The latter indicates 
a potentially long-lasting effect on fecal Kp occur-
rence after antibiotic exposure.
The findings that specific diseases and drug 
treatments, often used in hospital settings, were 
associated with Kp gastrointestinal carriage merit 
further research to understand how these modulate 
the gastrointestinal tract microbiota promoting Kp 
colonization. Diseases,21 drug use,25,31 and diet 
profiles34 which are shown to be associated with 
an increased abundance of Proteobacteria may con-
sequently also be associated with Kp carriage. In 
contrast, microbiome compositions favoring 
Firmicutes and Bacteroidetes were associated with 
a lower risk of Gram-negative intestinal domina-
tion and corresponding bloodstream infections.35 
Further studies are required to investigate the 
potential relationship between microbial composi-
tion and Kp carriage.
Alcohol consumption is an established factor in 
altering the gastrointestinal microbiota,36 however, 
the effect of alcohol on the abundance of different 
taxonomic phyla is vague.37 Studies investigating 
oropharyngeal Kp colonization have found 
a higher prevalence among alcoholic patients com-
pared to controls.38,39 In contrast, our data may 
indicate that more frequent alcohol intake might 
be associated with lower Kp gastrointestinal preva-
lence, but further studies including more cases are 
required.
Comparable to previous reports on Kp carriage 
isolates in pregnant women in the community- 
setting in low-income countries19 and hospitalized 
patients in high-income countries,14,15 we found 
a phylogenetically highly diverse Kp population 
with dominance of K. pneumoniae sensu stricto. 
This indicates individually adapted Kp populations 
with limited interconnection. The observed diver-
sity in our study may also be an underestimation 
due to the selection of only one colony for sequen-
cing. Considering the evidence that a high propor-
tion of Kp extraintestinal infections originate from 
the patients’ own carriage isolates,14,15 we assume 
that the Kp carriage population structure among 
individuals in the community is partly mirrored in 
the clinical setting. This is in line with the finding 
that six of the ten most prevalent STs of the carriage 
isolates also are among the ten most frequently 
observed STs in an ongoing Kp bacteremia study 
in Norway (unpublished data; Fostervold et al.). 
The high bacterial diversity provides important 
data in terms of vaccine prospects and the identifi-
cation of reservoirs as a potential source for human 
Kp colonization.5,40 The low level of antibiotic 
resistance in our study is consistent with national 
data in the clinical setting and reflects the relatively 
low antibiotic consumption in Norway.32
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This is the first study investigating the prevalence 
of Kp gastrointestinal carriage and associated risk 
factors in a large representative sample of a general 
adult population in a community setting in a high- 
income country. An important methodological 
strength is the high study attendance rate. We 
used data from nearly 3,000 people aged >40 y, 
thereby avoiding the substantial selection bias 
related to convenience samples in healthcare set-
tings. Major strengths also include the combined 
use of questionnaire data, drug use data from 
a national registry database, and both phenotypic 
and genomic laboratory results. The high-quality 
drug data enabled us to detect increasing Kp pre-
valence among participants having used two or 
three drug classes simultaneously, and additionally 
to assess the cumulative change over time in pro-
portion of Kp carriers associated with antibio-
tic use.
The age restriction is a limitation as we only 
studied adults >40 y. It would have been interesting 
to analyze Kp prevalence among those younger 
than 40 whom use less antibiotics and have fewer 
chronic diseases.32 As we found that Kp prevalence 
increased with age, extrapolation may suggest 
younger adults to have a lower prevalence. Diet 
and oral hygiene are well-known factors effecting 
gastrointestinal microbial composition34,41; how-
ever, such data were not available in our study. 
Due to lack of resources, we did not screen all 
available fecal samples for Kp carriage which 
would have further increased the precision of the 
estimates. We used selective SCAI medium for 
detection of Kp, as this strategy has been shown 
to have a high Kp recovery supporting the growth 
of all Kp phylogroups.42 However, we acknowledge 
that positive culturing could reflect those with 
a relative high abundance of Kp and that molecu-
lar-based approaches, which are less dependent on 
abundance and phenotypic differentiation, may 
detect an even higher prevalence of Kp carriage. 
We are currently in a follow-up study performing 
whole metagenomic sequencing on a subset of the 
fecal samples and SCAI sweeps to investigate the 
abundance of Kp, microbial composition of carriers 
and non-carriers, and the phylogroup/ST diversity 
within single individuals. Home sampling, as con-
ducted in our study, could be another biasing fac-
tor. However, we controlled for this by ensuring 
validity of the samples by assessing bacterial growth 
consistent with fecal flora on nonselective media 
and mean transport time from sampling to labora-
tory arrival was only 1.8 d.
In conclusion, our findings illustrate the associa-
tion of non-antibiotic drugs and inflammatory 
bowel diseases with increased prevalence of Kp 
gastrointestinal carriage that warrants considera-
tions with regard to risk stratification in the pre-
vention of healthcare-associated infections and 
opens up for potential future gut microbiome mod-
ulation interventions. The highly diverse popula-
tion structure of Kp colonizing humans illustrates 
the capacity for adaptive diversification of this spe-
cies complex. This is challenging for vaccine pro-
spects and complicates the identification of 
potential Kp cross-niche transmission, which will 
be important in detection of animal or environ-
mental Kp reservoirs for clinically relevant human 
Kp carriage and infection from a One Health 
perspective.
Subjects and methods
Study population and design
The Tromsø Study is a population-based study with 
repeated cross-sectional health surveys in the 
municipality of Tromsø, Norway. Tromsø is con-
sidered as representative of a Northern European, 
urban population.43 The seventh survey of the 
Tromsø Study (Tromsø 7, https://uit.no/research/ 
tromsostudy) was conducted from March 2015 to 
October 2016 and included two clinical visits. 
Unique national identity numbers from the official 
population-registry were used to invite all citizens 
>40 y (n = 33,423) (Figure 4). Sixty-five percent 
(n = 21,083, 11,074 women) attended the first clin-
ical visit in the study. A total of 9,324 participants 
attending the first visit were invited for a second 
visit. These represent a random selection of 20% in 
age-group 40–59 y and 50% in age-group 60–84 y 
of the initially invited participants (n = 33,423). To 
enhance the proportion of participants in earlier 
Tromsø Studies, 3,154 participants aged 40–84 y 
who had attended clinical examinations in 
Tromsø 6 were also invited. From March 2015 to 
March 2016, 5,800 of the 9,324 participants invited 
for the second visit were consecutively offered 
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a fecal self-sampling kit. In total, 87% (n = 5,042) 
returned a fecal sample either at the second visit, or 
by mail to the laboratory. Participants collected 
fecal material using nylon-flocked ESwab 490CE.A 
(Copan, Brescia, Italy). The first 3,009 of the 5,042 
collected fecal samples were consecutively screened 
for the presence of Kp via selective culture. Due to 
resource limitations, the remaining 2,033 samples 
were not screened. All participants completed two 
self-administered structured questionnaires on 
socio-demographics, smoking, alcohol use, hospi-
talization, chronic diseases, and travel abroad. After 
excluding 12 participants with wrong or missing 
sample identification number and 22 with missing 
questionnaires, our final study population con-
sisted of 2,975 participants.
To assess the participants’ drug use during 
the preceding 12 months, data from Tromsø 7 
were linked to the Norwegian Prescription 
Database (NorPD, http://www.norpd.no/).44 
NorPD contains detailed information at the 
individual level on all dispensed prescription- 
drugs at all pharmacies in Norway. We defined 
drugs dispensed as drugs used and included the 
following groups in the Anatomical Therapeutic 
Chemical (ATC) classification system: A02 
(acid-related disorders), A10 (diabetes), H03A 
(thyroid hormones), J01, A07AA09, P01AB01 
Figure 4. Flow diagram of study population.
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(antibacterials for systemic use), and M01 (anti- 
inflammatory and anti-rheumatic drugs).
Klebsiella pneumoniae isolation
Upon arrival in the laboratory, 200 µl 85% glycerol 
was added to each ESwab tube and the samples 
were stored at −80°C. From the thawed media, 
100 µl were plated onto Simmons citrate agar with 
inositol (SCAI) (both Sigma-Aldrich, Darmstadt, 
Germany) and incubated for 48 h at 37°C.42,45 
Large, yellow, glossy colonies suspected of being 
Klebsiella spp. were identified using mass spectro-
metry (MALDI-TOF, Bruker Daltonics, Bremen, 
Germany). The first colony identified as either 
K. pneumoniae or K. variicola from each sample 
was kept and further analyzed. All samples were 
plated on cysteine lactose electrolyte deficient agar 
(MAST Group, Bootle, UK) to assess growth of 
fecal flora and validity of the samples.
Antimicrobial susceptibility testing
Susceptibility testing was performed according to 
the EUCAST disk diffusion method and interpreted 
using the EUCAST 2021 breakpoint table (https:// 
eucast.org/).46
Genomic sequencing and bioinformatic analysis
DNA was extracted with the MagNA Pure 96 sys-
tem (Roche Applied Science, Mannheim, 
Germany) and sequencing libraries were prepared 
according to the Nextera Flex sample preparation 
protocol (Illumina, San Diego, CA, USA). 
Sequencing was performed on the Illumina MiSeq 
platform to generate 300 bp paired-end reads. All 
reads were trimmed with TrimGalore v0.6.4 and 
assembled with Unicycler v0.4.8 including SPAdes 
v3.13.0.47–49 Kleborate v2.0.0 was used to deter-
mine sequence type (ST), species identification, 
and acquired genes encoding virulence or antibiotic 
resistance.50,51 Kaptive was used to identify capsule 
biosynthesis loci (KL), and LPS (O) antigen 
loci.52,53 Plasmid replicons were identified with 
PlasmidFinder v2020-07-13 using Abricate v0.9.9 
(https://github.com/tseemann/abricate).54,55 Novel 
STs, blaSHV, blaLEN, blaOKP, and virulence alleles 
were assigned by the curators of the Institut 
Pasteur multilocus sequence type (MLST) and 
core genome MLST databases (https://bigsdb.pas 
teur.fr/klebsiella). To verify the absence of blaSHV 
/blaLEN, observed in two genomes, the raw reads 
were inspected with SRST2 v0.2.0.56
Phylogenetic analysis
To assess the phylogenetic relatedness, a core gen-
ome alignment of the 484 genomes against the 
K. pneumoniae ST23 NTUH-K2044 reference chro-
mosome (GenBank accession: NC_012731.1) was 
generated using the RedDog pipeline v1beta.11 
(https://github.com/katholt/RedDog), and inferred 
as described previously.57,58 To identify the number 
of single-nucleotide polymorphisms (SNPs) 
between any two genomes from the resulting align-
ment, snp-dists v0.7.0 (https://github.com/tsee 
mann/snp-dists/) was used.
Definition of hypervirulent Kp
Hypervirulent Kp were defined here according to 
Huynh et al., as isolates harboring at least one of the 
genes rmpA and rmpA2, and/or at least one com-
plete gene cluster among iucABCD-iutA (aerobac-
tin) and iroBCDN (salmochelin).19
Statistical analysis
The primary analysis was a multivariable logistic 
regression model with outcome variable being cul-
ture-confirmed Kp gastrointestinal carriage using 
SPSS v26.0 (SPSS, Inc., Chicago, IL, USA). A priori 
known or assumed variables associated with Kp 
carriage were selected with the help of a directed 
acyclic graph constructed using DAGitty v3.0 
(Suppl. Figure 1).59,60 All explanatory variables 
were kept in the fully adjusted model, independent 
of p-values. The strength of the associations was 
examined by calculating adjusted odds ratios 
(AORs) with 95% confidence intervals (CIs). Two- 
sided p-values <0.05 were considered statistically 
significant. Phylogroup subanalyses were per-
formed using χ2 test. We used R v4.0.0 
(Foundation for Statistical Computing, Vienna, 
Austria) to create a proportional Venn diagram 
for statistically significant drug groups associated 
with Kp carriage. STATA v16.1 (StataCorp LLC, 
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Texas, USA) was used to analyze the cumulative 
change in proportion of Kp carriers associated with 
antibiotic use in the past 1–12 months.
Acknowledgments
We are grateful for technical assistance from Bjørg Haldorsen, 
Bettina Aasnæs and Ellen Josefsen in organizing the collection 
of fecal samples in the laboratory. Eva Bernhoff and Ragna- 
Johanne Bakksjø for performing whole-genome sequencing. 
Dorota Buczek for creating the Venn diagram. Rod 
Wolstenholme for figure editing. We thank the team of cura-
tors of the Institut Pasteur MLST and whole-genome MLST 
databases for curating the data and making them publicly 
available at https://bigsdb.pasteur.fr/.
Disclosure of potential conflicts of interest
All authors report no conflicts of interest.
Author contributions
ØS conceptualized and acquired funding for the study in 
collaboration with AS, KG, IHL, SB and KH. ØS was respon-
sible for organizing the collection of fecal samples. LLEA did 
the screening of fecal samples and phenotypic testing. NR, KS, 
LS and KG conceptualized and conducted the epidemiological 
analysis of risk factors. IHL organized whole-genome sequen-
cing of isolates. MAKH, NR and ØS did the analysis of whole 
genome sequence data. SB and KH provided tools for genomic 
analysis and data curation. NR, MAKH, ØS, and KG prepared 
first manuscript draft. All authors contributed to review and 
editing of the manuscript and approved the final version.
Data availability
Bacterial genome data (raw Illumina reads) are publicly avail-
able in NCBI under BioProject PRJEB42350. This study is 
based on data owned by a third party (The Tromsø Study, 
Department of Community Medicine, UiT The Arctic 
University of Norway). Confidentiality requirements accord-
ing to Norwegian law prevent sharing of individual patient- 
level data in public repositories. Application of legal basis and 
exemption from professional secrecy requirements for the use 
of personal health data in research may be sent to a regional 
committee for medical and health research ethics (https:// 
rekportalen.no/). The authors gained access to the data 
through the Tromsø Study’s application process. Guidelines 
on how to access the data are available at the website https:// 
uit.no/research/tromsostudy. All enquiries about the Tromsø 
Study should be sent by e-mail to tromsous@ism.uit.no. All 
the questionnaire variables are published in the NESSTAR 
program system, and results can be viewed online: http:// 
tromsoundersokelsen.uit.no/tromso/.
Ethics
The study, including the linking of data between Tromsø 7 
and NorPD, was approved by the Regional Committee for 
Medical and Health Research Ethics, North Norway (REC 
North reference: 2016/1788 and 2014/940) and the Data 
Protection Officer at University Hospital of North Norway 
(reference: 2019/4264). The study complied with the 
Declaration of Helsinki. All participants in Tromsø 7 signed 
an informed consent form prior to participation.
Funding
This study was supported by grants from the Northern 
Norway Regional Health Authority [HNF1415-18] and The 
Trond Mohn Foundation [TMF2019TMT03]. The funders of 
the study played no role in study design, data collection, data 
analysis, data interpretation, or writing of the report.
ORCID
Niclas Raffelsberger http://orcid.org/0000-0002-9463-8915




Iren Høyland Löhr http://orcid.org/0000-0002-8847-0044
Sylvain Brisse http://orcid.org/0000-0002-2516-2108





1. Podschun R, Ullmann U. Klebsiella spp. as nosocomial 
pathogens: epidemiology, taxonomy, typing methods, 
and pathogenicity factors. Clin Microbiol Rev. 1998 
Oct;11(4):589–603. doi:10.1128/CMR.11.4.589.
2. Navon-Venezia S, Kondratyeva K, Carattoli A. 
Klebsiella pneumoniae: a major worldwide source and 
shuttle for antibiotic resistance. FEMS Microbiol Rev. 
2017 May 1;41(3):252–275. doi:10.1093/femsre/fux013.
3. Russo TA, Marr CM. Hypervirulent Klebsiella 
pneumoniae. Clin Microbiol Rev. 2019 May 15;32(3): 
e00001–19. doi:10.1128/CMR.00001-19.
4. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, 
Hoxha A, Simonsen GS, Colomb-Cotinat M, 
Kretzschmar ME, Devleesschauwer B, Cecchini M, 
et al. Attributable deaths and disability-adjusted 
life-years caused by infections with antibiotic-resistant 
bacteria in the EU and the European Economic Area in 
GUT MICROBES e1939599-11
2015: a population-level modelling analysis. Lancet 
Infect Dis. 2019 Jan;19(1):56–66. doi:10.1016/S1473- 
3099(18)30605-4.
5. Wyres KL, Holt KE. Klebsiella pneumoniae as a key 
trafficker of drug resistance genes from environmental 
to clinically important bacteria. Curr Opin Microbiol. 
2018 Oct;45:131–139. doi:10.1016/j.mib.2018.04.004.
6. Tacconelli E, Carrara E, Savoldi A, Harbarth S, 
Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, 
Kluytmans J, Carmeli Y, et al. Discovery, research, and 
development of new antibiotics: the WHO priority list 
of antibiotic-resistant bacteria and tuberculosis. Lancet 
Infect Dis. 2018 Mar;18(3):318–327. doi:10.1016/S1473- 
3099(17)30753-3.
7. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, 
Criscuolo A, Brisse S. Description of Klebsiella africa-
nensis sp. nov., Klebsiella variicola subsp. tropicalensis 
subsp. nov. and Klebsiella variicola subsp. variicola 
subsp. nov. Res Microbiol. 2019 Apr-May;170 
(3):165–170. doi:10.1016/j.resmic.2019.02.003.
8. Wyres KL, Lam MMC, Holt KE. Population genomics 
of Klebsiella pneumoniae. Nat Rev Microbiol. 2020 
June;18(6):344–359. doi:10.1038/s41579-019-0315-1.
9. Brisse S, Verhoef J. Phylogenetic diversity of Klebsiella 
pneumoniae and Klebsiella oxytoca clinical isolates 
revealed by randomly amplified polymorphic DNA, 
gyrA and parC genes sequencing and automated 
ribotyping. Int J Syst Evol Microbiol. 2001 May;51(Pt 
3):915–924. doi:10.1099/00207713-51-3-915.
10. Rosenblueth M, Martinez L, Silva J, Martinez-Romero 
E. Klebsiella variicola, a novel species with clinical and 
plant-associated isolates. Syst Appl Microbiol. 2004 
Feb;27(1):27–35. doi:10.1078/0723-2020-00261.
11. Brisse S, Passet V, Grimont PA. Description of 
Klebsiella quasipneumoniae sp. nov., isolated from 
human infections, with two subspecies, Klebsiella qua-
sipneumoniae subsp. quasipneumoniae subsp. nov. and 
Klebsiella quasipneumoniae subsp. similipneumoniae 
subsp. nov., and demonstration that Klebsiella singapor-
ensis is a junior heterotypic synonym of Klebsiella 
variicola. Int J Syst Evol Microbiol. 2014 Sept;64(Pt 
9):3146–3152. doi:10.1099/ijs.0.062737-0.
12. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, 
Criscuolo A, Brisse S. Erratum to “Description of 
Klebsiella africanensis sp. nov., Klebsiella variicola 
subsp. tropicalensis subsp. nov. and Klebsiella variicola 
subsp. variicola subsp. nov”. [Res Microbiol 170 (3) 
(2019) 165-170]. Res Microbiol. 2019 Sept-Oct;170(6– 
7):300. doi:10.1016/j.resmic.2019.09.001.
13. Selden R, Lee S, Wang WL, Bennett JV, Eickhoff TC. 
Nosocomial klebsiella infections: intestinal colonization 
as a reservoir. Ann Intern Med. 1971 May;74 
(5):657–664. doi:10.7326/0003-4819-74-5-657.
14. Gorrie CL, Mirceta M, Wick RR, Edwards DJ, 
Thomson NR, Strugnell RA, Pratt NF, Garlick JS, 
Watson KM, Pilcher DV, et al. Gastrointestinal carriage 
is a major reservoir of K. pneumoniae infection in 
intensive care patients. Clin Infect Dis. 2017 July 15;65 
(2):208–215. doi:10.1093/cid/cix270.
15. Martin RM, Cao J, Brisse S, Passet V, Wu W, Zhao L, 
Malani PN, Rao K, Bachman MA, et al. Molecular 
epidemiology of colonizing and infecting isolates of 
Klebsiella pneumoniae. mSphere. 2016 Oct 19;1(5): 
e00261–16. doi:10.1128/mSphere.00261-16.
16. Shimasaki T, Seekatz A, Bassis C, Rhee Y, Yelin RD, 
Fogg L, Dangana T, Cisneros EC, Weinstein RA, 
Okamoto K, et al. Increased relative abundance of 
Klebsiella pneumoniae carbapenemase-producing 
Klebsiella pneumoniae within the gut microbiota is asso-
ciated with risk of bloodstream infection in long-term 
acute care hospital patients. Clin Infect Dis. 2019 May 
30;68(12):2053–2059. doi:10.1093/cid/ciy796.
17. Chung DR, Lee H, Park MH, Jung S-I, Chang -H-H, 
Kim Y-S, Son JS, Moon C, Kwon KT, Ryu SY, et al. Fecal 
carriage of serotype K1 Klebsiella pneumoniae ST23 
strains closely related to liver abscess isolates in 
Koreans living in Korea. Eur J Clin Microbiol Infect 
Dis. 2012 Apr;31(4):481–486. doi:10.1007/s10096-011- 
1334-7.
18. Lin YT, Siu LK, Lin JC, Chen T-L, Tseng C-P, Yeh K-M, 
Chang F-Y, Fung C-P. Seroepidemiology of Klebsiella 
pneumoniae colonizing the intestinal tract of healthy 
Chinese and overseas Chinese adults in Asian 
countries. BMC Microbiol. 2012;12:13. doi:10.1186/ 
1471-2180-12-13.
19. Huynh BT, Passet V, Rakotondrasoa A, Diallo T, 
Kerleguer A, Hennart M, Lauzanne AD, 
Herindrainy P, Seck A, Bercion R, et al. Klebsiella pneu-
moniae carriage in low-income countries: antimicrobial 
resistance, genomic diversity and risk factors. Gut 
Microbes. 2020 Sept 2;11(5):1287–1299. doi:10.1080/ 
19490976.2020.1748257.
20. Simpson EH. Measurement of diversity. Nature. 
1949;163:688. doi:10.1038/163688a0.
21. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, 
Van Treuren W, Ren B, Schwager E, Knights D, Song S, 
Yassour M, et al. The treatment-naive microbiome in 
new-onset Crohn’s disease. Cell Host Microbe. 2014 
Mar 12;15(3):382–392. doi:10.1016/j.chom.2014.02.005.
22. Kaur CP, Vadivelu J, Chandramathi S. Impact of 
Klebsiella pneumoniae in lower gastrointestinal tract 
diseases. J Dig Dis. 2018 May;19(5):262–271. 
doi:10.1111/1751-2980.12595.
23. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, 
Andoh A. Gut microbiota in the pathogenesis of inflam-
matory bowel disease. Clin J Gastroenterol. 2018 Feb;11 
(1):1–10. doi:10.1007/s12328-017-0813-5.
24. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, 
Anderson EE, Brochado AR, Fernandez KC, Dose H, 
Mori H, et al. Extensive impact of non-antibiotic drugs 
on human gut bacteria. Nature. 2018 Mar 29;555 
(7698):623–628. doi:10.1038/nature25979.
25. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, 
Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, 
e1939599-12 N. RAFFELSBERGER ET AL.
Harmsen HJM, et al. Proton pump inhibitors affect the 
gut microbiome. Gut. 2016 May;65(5):740–748. 
doi:10.1136/gutjnl-2015-310376.
26. Reveles KR, Ryan CN, Chan L, Cosimi RA, Haynes WL. 
Proton pump inhibitor use associated with changes in 
gut microbiota composition. Gut. 2018;67 
(7):1369–1370. doi:10.1136/gutjnl-2017-315306.
27. Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke- 
Grauls C. Evaluation of the association between gastric 
acid suppression and risk of intestinal colonization with 
multidrug-resistant microorganisms: a systematic 
review and meta-analysis. JAMA Intern Med. 2020 
Apr 1;180(4):561–571. doi:10.1001/ 
jamainternmed.2020.0009.
28. Bavishi C, Dupont HL. Systematic review: the use of 
proton pump inhibitors and increased susceptibility to 
enteric infection. Aliment Pharmacol Ther. 2011 Dec;34 
(11–12):1269–1281. doi:10.1111/j.1365- 
2036.2011.04874.x.
29. Wang JH, Liu YC, Lee SS, Yen M-Y, Wang YSCH, 
Wann S-R, Lin -H-H. Primary Liver Abscess Due to 
Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 1998 
June;26(6):1434–1438. doi:10.1086/516369.
30. Wang YP, Liu CJ, Chen TJ, Lin YT, Fung CP. Proton 
pump inhibitor use significantly increases the risk of 
cryptogenic liver abscess: a population-based study. 
Aliment Pharmacol Ther. 2015 June;41(11):1175–1181. 
doi:10.1111/apt.13203.
31. Rogers MAM, Aronoff DM. The influence of 
non-steroidal anti-inflammatory drugs on the gut 
microbiome. Clin Microbiol Infect. 2016 Feb;22 
(2):178.e1–178.e9. doi:10.1016/j.cmi.2015.10.003.
32. NORM/NORM-VET 2019. Usage of antimicrobial 
agents and occurrence of antimicrobial resistance in 
Norway. Tromsø/Oslo; 2020. 1502-2307 (print)/1890- 
9965 (electronic).
33. Willing BP, Russell SL, Finlay BB. Shifting the balance: 
antibiotic effects on host-microbiota mutualism. Nat 
Rev Microbiol. 2011 Apr;9(4):233–243. doi:10.1038/ 
nrmicro2536.
34. Zmora N, Suez J, Elinav E. You are what you eat: diet, 
health and the gut microbiota. Nat Rev Gastroenterol 
Hepatol. 2019 Jan;16(1):35–56.
35. Stoma I, Littmann ER, Peled JU, Giralt S, van den 
Brink MR, Pamer EG, Taur Y. Compositional flux 
within the intestinal microbiota and risk for blood-
stream infection with gram-negative bacteria. Clin 
Infect Dis. 2020 Jan 24;ciaa068. doi:10.1093/cid/ciaa068.
36. Bjorkhaug ST, Aanes H, Neupane SP, Bramness JG, 
Malvik S, Henriksen C, Skar V, Medhus AW, Valeur J. 
Characterization of gut microbiota composition and 
functions in patients with chronic alcohol 
overconsumption. Gut Microbes. 2019;10(6):663–675. 
doi:10.1080/19490976.2019.1580097.
37. Lee E, Lee JE. Impact of drinking alcohol on gut micro-
biota: recent perspectives on ethanol and alcoholic 
beverage. Curr Opin Food Sci. 2021;37:91–97. 
doi:10.1016/j.cofs.2020.10.001.
38. Fuxench-Lopez Z, Ramirez-Ronda CH. Pharyngeal 
flora in ambulatory alcoholic patients: prevalence of 
gram-negative bacilli. Arch Intern Med. 1978 Dec;138 
(12):1815–1816. doi:10.1001/ 
archinte.1978.03630370033017.
39. Dao TT, Liebenthal D, Tran TK, Ngoc Thi Vu B, Ngoc 
Thi Nguyen D, Thi Tran HK, Thi Nguyen CK, Thi 
Vu HL, Fox A, Horby P, et al. Klebsiella pneumoniae 
oropharyngeal carriage in rural and urban Vietnam and 
the effect of alcohol consumption. PLoS One. 2014 Mar 
25;9(3):e91999. doi:10.1371/journal.pone.0091999.
40. Lipworth S, Vihta KD, Chau KK, Kavanagh J, Davies T, 
George S, Barker L, Vaughan A, Andersson M, 
Jeffery K, et al. Ten years of population-level genomic 
Escherichia coli and Klebsiella pneumoniae serotype 
surveillance informs vaccine development for invasive 
infections. Clin Infect Dis. 2021 Jan 7;ciab006. 
doi:10.1093/cid/ciab006.
41. Olsen I, Yamazaki K. Can oral bacteria affect the micro-
biome of the gut? J Oral Microbiol. 2019 Mar 18;11 
(1):1586422. doi:10.1080/20002297.2019.1586422.
42. Passet V, Brisse S. Association of tellurite resistance 
with hypervirulent clonal groups of Klebsiella 
pneumoniae. J Clin Microbiol. 2015 Apr;53 
(4):1380–1382. doi:10.1128/JCM.03053-14.
43. Eggen AE, Mathiesen EB, Wilsgaard T, Jacobsen BK, 
Njolstad I. The sixth survey of the Tromso Study 
(Tromso 6) in 2007-08: collaborative research in the 
interface between clinical medicine and epidemiology: 
study objectives, design, data collection procedures, and 
attendance in a multipurpose population-based health 
survey. Scand J Public Health. 2013 Feb;41(1):65–80. 
doi:10.1177/1403494812469851.
44. Furu K. Establishment of the nationwide Norwegian 
Prescription Database (NorPD) – new opportunities 
for research in pharmacoepidemiology in Norway. 
Norsk Epidemiologi. 2009;18(2). doi:10.5324/nje. 
v18i2.23.
45. Van Kregten E, Westerdaal NA, Willers JM. New, sim-
ple medium for selective recovery of Klebsiella pneumo-
niae and Klebsiella oxytoca from human feces. J Clin 
Microbiol. 1984 Nov;20(5):936–941. doi:10.1128/ 
jcm.20.5.936-941.1984.
46. Matuschek E, Brown DF, Kahlmeter G. Development of 
the EUCAST disk diffusion antimicrobial susceptibility 
testing method and its implementation in routine 
microbiology laboratories. Clin Microbiol Infect. 2014 
Apr;20(4):O255–66. doi:10.1111/1469-0691.12373.
47. Krueger F. TrimGalore v0.6.4. August 2019. https:// 
github.com/FelixKrueger/TrimGalore .
48. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: 
resolving bacterial genome assemblies from short and 
long sequencing reads. PLoS Comput Biol. 2017 June 
8;13(6):e1005595. doi:10.1371/journal.pcbi.1005595.
GUT MICROBES e1939599-13
49. Bankevich A, Nurk S, Antipov D, Gurevich AA, 
Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, 
Pham S, Prjibelski AD, et al. SPAdes: a new genome 
assembly algorithm and its applications to single-cell 
sequencing. J Comput Biol. 2012 May;19(5):455–477. 
doi:10.1089/cmb.2012.0021.
50. Lam MM, Wick RR, Wyres KL, Holt KE. Genomic 
surveillance framework and global population structure 
for Klebsiella pneumoniae. bioRxiv. 2020. doi:10.1101/ 
2020.12.14.422303.
51. Lam MMC, Wyres KL, Judd LM, Wick RR, Jenney A, 
Brisse S, Holt KE. Tracking key virulence loci encoding 
aerobactin and salmochelin siderophore synthesis in 
Klebsiella pneumoniae. Genome Med. 2018 Oct 29;10 
(1):77. doi:10.1186/s13073-018-0587-5.
52. Wyres KL, Wick RR, Gorrie C, Jenney A, Follador R, 
Thomson NR, Holt KE. Identification of Klebsiella cap-
sule synthesis loci from whole genome data. Microb 
Genom. 2016 Dec 12;2(12):e000102.
53. Wick RR, Heinz E, Holt KE, Wyres KL. Kaptive Web: 
user-friendly capsule and lipopolysaccharide serotype pre-
diction for Klebsiella genomes. J Clin Microbiol. 2018 May 
25;56(6):e00197–18. doi:10.1128/JCM.00197-18.
54. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby 
Larsen M, Lund O, Villa L, Møller Aarestrup F, 
Hasman H. In silico detection and typing of plasmids 
using Plasmidfinder and plasmid multilocus sequence 
typing. Antimicrob Agents Chemother. 2014 July;58 
(7):3895–3903. doi:10.1128/AAC.02412-14.
55. Seemann T. Abricate v0.9.9, Github. February 2020. 
https://github.com/tseemann/abricate .
56. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, 
Tomita T, Zobel J, Holt KE. SRST2: rapid genomic 
surveillance for public health and hospital microbiology 
labs. Genome Med. 2014 Nov 20;6(11):90. doi:10.1186/ 
s13073-014-0090-6.
57. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, 
Gorrie CL, Lam MMC, Duchêne S, Jenney A, Holt KE, 
et al. Distinct evolutionary dynamics of horizontal gene 
transfer in drug resistant and virulent clones of 
Klebsiella pneumoniae. PLoS Genet. 2019 Apr 15;15(4): 
e1008114. doi:10.1371/journal.pgen.1008114.
58. Price MN, Dehal PS, Arkin AP. FastTree 2-- 
approximately maximum-likelihood trees for large 
alignments. PLoS One. 2010 Mar 10;5(3):e9490. 
doi:10.1371/journal.pone.0009490.
59. Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, 
Ellison GT. Robust causal inference using directed acyc-
lic graphs: the R package ‘dagitty’. Int J Epidemiol. 2016 
Dec 1;45(6):1887–1894. doi:10.1093/ije/dyw341.
60. Williams TC, Bach CC, Matthiesen NB, Henriksen TB, 
Gagliardi L. Directed acyclic graphs: a tool for causal 
studies in paediatrics. Pediatr Res. 2018 Oct;84 
(4):487–493. doi:10.1038/s41390-018-0071-3.
e1939599-14 N. RAFFELSBERGER ET AL.
